298 studies found for:    CLL [CONDITION] | Open Studies
Show Display Options
Rank Status Study
1 Unknown  Multi-center Trial of Revlimid® and Rituximab, for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   CLL;   Untreated;   Front-line;   First-Line;   Initial Therapy
Intervention: Drug: Lenalidomide and Rituximab
2 Recruiting Natural Killer Cells and Bortezomib to Treat Cancer
Conditions: Lung or Prostatic Neoplasms;   Colorectal or Kidney Neoplasms;   Pancreatic Neoplasms;   Leukemia, Myelogenous, Chronic Lymphocytic Leukemia, BCR-ABL Positive;   Melanoma;   CLL
Intervention: Drug: NK cells +CliniMACs CD3 and CD56 systems
3 Unknown  Multi-center Trial of Revlimid® and Rituximab for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   CLL
Interventions: Drug: Revlimid, rituximab;   Drug: Relapsed or refractory CLL. Lenalidomide and Rituximab
4 Recruiting Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients
Conditions: CLL;   B-cell;   Small Lymphocytic Lymphoma;   Untreated B-CLL;   Elderly Patients
Intervention:
5 Recruiting A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Conditions: Small Lymphocytic Lymphoma;   CLL (Chronic Lymphocytic Leukemia)
Interventions: Drug: Fludarabine Phosphate;   Biological: Ofatumumab;   Drug: Cyclophosphamide
6 Recruiting Phase II Study of Bendamustine and Rituximab Induction Chemoimmunotherapy Followed by Maintenance Rituximab (Rituxan®) and Lenalidomide (Revlimid®) in Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma (SLL)
Interventions: Drug: Bendamustine Hydrochloride;   Drug: Rituximab;   Drug: Lenalidomid
7 Recruiting Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in 17p- Chronic Lymphocytic Leukemia (CLL)
Condition: CLL
Intervention:
8 Recruiting Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL
Conditions: CLL;   SLL
Interventions: Drug: Ofatumumab;   Drug: High-Dose Methylprednisolone;   Drug: Alemtuzumab
9 Recruiting Vaccine Therapy for Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Biological: Oncoquest-CLL vaccine
10 Recruiting Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
Conditions: Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
Interventions: Biological: MOR00208;   Drug: lenalidomide;   Other: Correlative Studies
11 Recruiting Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
Condition: B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion
Interventions: Drug: Idelalisib;   Drug: Rituximab
12 Recruiting Phase II Protocol for CLL With Fludarabine and Cyclophosphamide With Rituximab (FCR) Plus Lenalidomide
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide
13 Recruiting A Study of Dasatinib in Chronic Lymphocytic Leukemia in Patients Who Exhibit in Vitro Dasatinib Sensitivity
Condition: Chronic Lymphocytic Leukemia (CLL)
Intervention: Drug: Dasatinib
14 Recruiting Intensified Rituimab Prephase Before FCR in Untreated B-CLL
Condition: B-cell Chronic Lymphocytic Leukemia CLL
Interventions: Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Fludarabine
15 Recruiting Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation
Conditions: Acute Lymphoblastic Leukemia (ALL);   Acute Myelogenous Leukemia (AML);   Chronic Lymphocytic Leukemia (CLL);   Chronic Myelogenous Leukemia (CML);   MDS
Intervention: Device: CliniMACS CD34 selection system
16 Recruiting IL-15 Super Agonist ALT-803 to Treat Relapse Of Hematologic Malignancy After Allogeneic SCT
Conditions: Acute Myelogenous Leukemia (AML);   Acute Lymphoblastic Leukemia (ALL);   Myelodysplastic Syndromes (MDS);   Lymphoma;   Myeloma;   Chronic Lymphocytic Leukemia (CLL);   Chronic Myelogenous Leukemia (CML)
Intervention: Biological: ALT-803
17 Recruiting Cord Blood Transplant
Conditions: Chronic Myelogenous Leukemia (CML);   Acute Myelogenous Leukemia (AML);   Myelodysplastic Syndrome;   Multiple Myeloma;   Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia (CLL);   Acute Lymphocytic Leukemia (ALL);   Severe Aplastic Anemia
Intervention: Genetic: umbilical cord transplant (UCB)
18 Recruiting Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
Conditions: Acute Lymphoblastic Leukemia (ALL);   Chronic Lymphocytic Leukemia (CLL);   Non Hodgkin's Lymphoma
Intervention: Genetic: CD19CAR/virus specific T cells
19 Recruiting Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)
Conditions: Chronic Lymphocytic Leukaemia (CLL);   Indolent Non Hodgkin's Lymphoma (iNHL)
Intervention:
20 Recruiting Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   CLL;   SLL
Intervention: Drug: A6

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years